[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • After treatment with anti-viral drugs the vesicular eruption disappeared, but chest X-ray film revealed a right diaphragmatic relaxation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Herpes Zoster / complications. Respiratory Paralysis / etiology
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon KokyuÌ„ki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


2. Abe A, Yamane M, Yamada H, Sugawara I: The omega-hydroxy palmitic acid induced apoptosis in human lung carcinoma cell lines H596 and A549. J Biochem Mol Biol Biophys; 2002 Feb;6(1):37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The omega-hydroxy palmitic acid induced apoptosis in human lung carcinoma cell lines H596 and A549.
  • We have found that omega-hydroxy palmitic acid (16-hydroxy palmitic acid, omega-HPA) has both cell growth inhibiting and cell death inducing actions on human lung adenosquamous carcinoma cell line H596 and adenocarcinoma cell line A549.
  • Further, these effects were dose- and time-dependent in both cell lines.
  • However, in squamous carcinoma cell line H226, omega-HPA had no cytotoxic effect.
  • On the other hand, in the human small cell lung carcinoma (SCLC) cell line H128, this compound showed weak cytotoxicity.
  • In both H596 and A549 cells, cell growth was inhibited to 24.4 and 9.4%, respectively, by treatment with 100 microM omega-HPA for 12 h.
  • Further, the fragmentation of DNA to oligonucleosomal-sized ladder fragments, which is an index of apoptosis, was observed in both cell lines on treatment with omega-HPA.
  • Therefore, it is assumed that these cell deaths induced by omega-HPA, were apoptosis in these cell lines.
  • Since the number of dead cells following treatment with omega-HPA decreased by treatment with omega-HPA in combination with Z-VAD-fmk, a caspase family inhibitor, it is thought that apoptotic cell death was related to caspase activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Apoptosis. Carcinoma / drug therapy. Lung Neoplasms / drug therapy. Palmitic Acids / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Amino Acid Chloromethyl Ketones / pharmacology. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Caspase Inhibitors. Cell Division. Cell Line. Cell Survival. Cysteine Proteinase Inhibitors / pharmacology. DNA Fragmentation / drug effects. DNA, Neoplasm / ultrastructure. Dose-Response Relationship, Drug. Humans. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186781.001).
  • [ISSN] 1025-8140
  • [Journal-full-title] Journal of biochemistry, molecular biology, and biophysics : JBMBB : the official journal of the Federation of Asian and Oceanian Biochemists and Molecular Biologists (FAOBMB)
  • [ISO-abbreviation] J. Biochem. Mol. Biol. Biophys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Antineoplastic Agents, Phytogenic; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / DNA, Neoplasm; 0 / Palmitic Acids; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 7IPP3U0F3I / 16-hydroxypalmitic acid
  •  go-up   go-down


3. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Bronchial Neoplasms / classification. Bronchial Neoplasms / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


Advertisement
4. Spizzo G, Seeber A, Mitterer M: Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. Anticancer Res; 2009 Dec;29(12):5245-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: No data on the tolerability and effects of pamidronate in non-small cell lung cancer patients with bone metastasis are available.
  • CONCLUSION: The diagnosis of bone metastasis and the consequent routine administration of pamidronate have an impact on survival of NSCLC patients; this drug is a good candidate for routine use in haemato-oncological centres.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044644.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


5. Sekine I, Matsuda T, Saisho T, Watanabe H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N: Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity. Jpn J Clin Oncol; 2000 Sep;30(9):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity.
  • Although neutropenia increases the risk of life-threatening infections, bacterial meningitis is rarely encountered as a complication during cancer chemotherapy in adults with a solid tumor.
  • A 66-year-old male with adenosquamous carcinoma of the lung, cT2N3M0, stage IIIB, was enrolled in a phase I trial of chemoradiotherapy and treated with cisplatin 80 mg/m2 (122 mg/ body) on day 1, vinorelbine 20 mg/m2 (32 mg/body) on days 1 and 8 and thoracic radiotherapy 30 Gy/15 fractions, beginning on day 2, with dexamethasone administered for antiemesis at a dose of 16 mg on day 1, 8 mg on days 2 and 3, 4 mg on day 4 and 2 mg on day 5.
  • In spite of the doctor's delay in establishing the exact diagnosis, the bacterial meningitis in this case was successfully treated with intensive antibiotic therapy.
  • This life-threatening complication, equivalent to a grade 4 non-hematological adverse reaction, was not counted as dose-limiting toxicity in the current phase I trial, because there are only a few reports of bacterial meningitis associated with cancer chemotherapy and it developed in this case without any associated decrease in the peripheral blood leukocyte count.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Meningitis, Bacterial / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Amikacin / administration & dosage. Antiemetics / administration & dosage. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cranial Irradiation. Dexamethasone / administration & dosage. Drug Therapy, Combination / administration & dosage. Humans. Male. Thienamycins / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bacterial Meningitis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIKACIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11095138.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Thienamycins; 5V9KLZ54CY / Vinblastine; 7S5I7G3JQL / Dexamethasone; 84319SGC3C / Amikacin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; W9769W09JF / panipenem
  • [Number-of-references] 23
  •  go-up   go-down


6. Sairenji T, Fujii Y, Eriguchi M: [A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11].
  • After examination of a 64-year-old man with dysphagia who consulted our hospital, a diagnosis was made an esophageal small-cell carcinoma.
  • This tumor had infiltrated the aorta and upon further examination another carcinoma, trachial adenosquamous cell carcinoma was found.
  • We know that CPT-11 is effective in the treatment of lung small-cell carcinoma, leading us to a decision to use CPT-11 for the second systemic chemotherapy.
  • As a result of 8 courses, the tumor minification rate was 64% with PR.
  • After completing 13 courses, the patient could ingest any type of food.
  • He transferred to another hospital for laser therapy for his trachial carcinoma.
  • To date the treatment of patients with esophageal small-cell carcinoma with chemotherapy using CPT-11 has not been reported.
  • We suggest that CPT-11 is an effective therapy in improving the condition of patients QOL with esophageal small-cell carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / therapeutic use. Carcinoma, Small Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579641.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion


8. Jusuf A, Mariono SA, Tambunan KL, Reksodiputro AH, Soetandyo N, Hukom R, Suratman E, Jayusman AM: Experience of treatment of lung cancer patients using paclitaxel and carboplatin. Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of treatment of lung cancer patients using paclitaxel and carboplatin.
  • Nineteen patients with stage III & IV nonsmall cell lung cancer were treated with a regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina Central General Hospital, Jakarta, Indonesia.
  • There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in 1 patient.
  • Fourteen patients were in stage IV, 4 had stage IIIB, and one had stage IIIA disease.
  • The regimen contained paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml.min, given every 3 weeks.
  • Objective improvement (PR) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895195.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 7
  •  go-up   go-down






Advertisement